Filing Details
- Accession Number:
- 0000950170-25-050559
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2025-04-03 17:00:10
- Reporting Period:
- 2025-04-01
- Filing Date:
- 2025-04-03
- Accepted Time:
- 2025-04-03 17:00:10
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1840574 | Verve Therapeutics Inc. | VERV | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1625110 | Allison Dorval | C/O Verve Therapeutics, Inc. 201 Brookline Avenue, Suite 601 Boston MA 02215 | Chief Financial Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2025-04-01 | 11,250 | $0.00 | 16,630 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2025-04-02 | 3,350 | $4.15 | 13,280 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Restricted Stock Units | Disposition | 2025-04-01 | 11,250 | $0.00 | 11,250 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 33,750 | No | 4 | M | Direct |
Footnotes
- Restricted stock units ("RSUs") convert into common stock on a one-for-one basis. This transaction represents the settlement of RSUs in shares of common stock on their scheduled vesting date.
- This transaction was effected pursuant to a durable automatic sale instruction plan adopted by the reporting person on March 20, 2023, and represents a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units. The sale does not represent a discretionary trade by the reporting person.
- On February 14, 2024, the reporting person was granted 45,000 RSUs pursuant to the Verve Therapeutics, Inc. 2021 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of the Company's common stock upon vesting, with 25% of the RSU vesting on April 1, 2025 and the remainder vesting in equal annual installments until April 1, 2028.
Billionaire Hedge Funds
